Literature DB >> 29679469

Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium.

Sook Wah Yee1, Deanna J Brackman1, Elizabeth A Ennis1, Yuichi Sugiyama2, Landry K Kamdem3, Rebecca Blanchard4, Aleksandra Galetin5, Lei Zhang6, Kathleen M Giacomini1,7.   

Abstract

Advances in genomic technologies have led to a wealth of information identifying genetic polymorphisms in membrane transporters, specifically how these polymorphisms affect drug disposition and response. This review describes the current perspective of the International Transporter Consortium (ITC) on clinically important polymorphisms in membrane transporters. ITC suggests that, in addition to previously recommended polymorphisms in ABCG2 (BCRP) and SLCO1B1 (OATP1B1), polymorphisms in the emerging transporter, SLC22A1 (OCT1), be considered during drug development. Collectively, polymorphisms in these transporters are important determinants of interindividual differences in the levels, toxicities, and response to many drugs.
© 2018 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29679469      PMCID： PMC6348109          DOI： 10.1002/cpt.1098

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  108 in total

1.  High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.

Authors:  Thomas Rau; Birgit Erney; Ralf Göres; Thomas Eschenhagen; Jörn Beck; Thorsten Langer
Journal:  Clin Pharmacol Ther       Date:  2006-11       Impact factor: 6.875

Review 2.  ABCB1 pharmacogenetics: progress, pitfalls, and promise.

Authors:  L W Chinn; D L Kroetz
Journal:  Clin Pharmacol Ther       Date:  2007-02       Impact factor: 6.875

3.  The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c.

Authors:  Mette M H Christensen; Charlotte Brasch-Andersen; Henrik Green; Flemming Nielsen; Per Damkier; Henning Beck-Nielsen; Kim Brosen
Journal:  Pharmacogenet Genomics       Date:  2011-12       Impact factor: 2.089

4.  Differing effects of metformin on glycemic control by race-ethnicity.

Authors:  L Keoki Williams; Badri Padhukasahasram; Brian K Ahmedani; Edward L Peterson; Karen E Wells; Esteban González Burchard; David E Lanfear
Journal:  J Clin Endocrinol Metab       Date:  2014-06-12       Impact factor: 5.958

5.  Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake.

Authors:  Min-Koo Choi; Im-Sook Song
Journal:  Biopharm Drug Dispos       Date:  2012-03-17       Impact factor: 1.627

6.  Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.

Authors:  Yan Shu; Steven A Sheardown; Chaline Brown; Ryan P Owen; Shuzhong Zhang; Richard A Castro; Alexandra G Ianculescu; Lin Yue; Joan C Lo; Esteban G Burchard; Claire M Brett; Kathleen M Giacomini
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

7.  Transport vs. Metabolism: What Determines the Pharmacokinetics and Pharmacodynamics of Drugs? Insights From the Extended Clearance Model.

Authors:  G Patilea-Vrana; J D Unadkat
Journal:  Clin Pharmacol Ther       Date:  2016-08-27       Impact factor: 6.875

8.  Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.

Authors:  Luciene Terezina de Lima; Carolina Tosin Bueno; Douglas Vivona; Rosario Domiguez Crespo Hirata; Mario Hiroyuki Hirata; Vania Tiestsche de Moraes Hungria; Carlos Sérgio Chiattone; Maria Aparecida Zanichelli; Maria de Lourdes Lopes Ferrari Chauffaille; Elvira Maria Guerra-Shinohara
Journal:  Hematology       Date:  2014-07-24       Impact factor: 2.269

9.  Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data.

Authors:  Joshua C Denny; Lisa Bastarache; Marylyn D Ritchie; Robert J Carroll; Raquel Zink; Jonathan D Mosley; Julie R Field; Jill M Pulley; Andrea H Ramirez; Erica Bowton; Melissa A Basford; David S Carrell; Peggy L Peissig; Abel N Kho; Jennifer A Pacheco; Luke V Rasmussen; David R Crosslin; Paul K Crane; Jyotishman Pathak; Suzette J Bielinski; Sarah A Pendergrass; Hua Xu; Lucia A Hindorff; Rongling Li; Teri A Manolio; Christopher G Chute; Rex L Chisholm; Eric B Larson; Gail P Jarvik; Murray H Brilliant; Catherine A McCarty; Iftikhar J Kullo; Jonathan L Haines; Dana C Crawford; Daniel R Masys; Dan M Roden
Journal:  Nat Biotechnol       Date:  2013-12       Impact factor: 54.908

10.  Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics.

Authors:  Päivi Hirvensalo; Aleksi Tornio; Mikko Neuvonen; Tuija Tapaninen; Maria Paile-Hyvärinen; Vesa Kärjä; Ville T Männistö; Jussi Pihlajamäki; Janne T Backman; Mikko Niemi
Journal:  Clin Pharmacol Ther       Date:  2017-11-06       Impact factor: 6.875
View more
  29 in total

Review 1.  Pharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation.

Authors:  Camille Tron; Florian Lemaitre; Céline Verstuyft; Antoine Petitcollin; Marie-Clémence Verdier; Eric Bellissant
Journal:  Clin Pharmacokinet       Date:  2019-05       Impact factor: 6.447

2.  Interactions of Oral Molecular Excipients with Breast Cancer Resistance Protein, BCRP.

Authors:  Ling Zou; Joshua Pottel; Natalia Khuri; Huy X Ngo; Zhanglin Ni; Eleftheria Tsakalozou; Mark S Warren; Yong Huang; Brian K Shoichet; Kathleen M Giacomini
Journal:  Mol Pharm       Date:  2020-02-10       Impact factor: 4.939

Review 3.  Comparison of Canine and Human Physiological Factors: Understanding Interspecies Differences that Impact Drug Pharmacokinetics.

Authors:  Marilyn N Martinez; Jonathan P Mochel; Sibylle Neuhoff; Devendra Pade
Journal:  AAPS J       Date:  2021-04-27       Impact factor: 4.009

4.  Characterization of Plasma Membrane Localization and Phosphorylation Status of Organic Anion Transporting Polypeptide (OATP) 1B1 c.521 T>C Nonsynonymous Single-Nucleotide Polymorphism.

Authors:  Alexandra Crowe; Wei Zheng; Jonathan Miller; Sonia Pahwa; Khondoker Alam; Kar-Ming Fung; Erin Rubin; Feng Yin; Kai Ding; Wei Yue
Journal:  Pharm Res       Date:  2019-05-15       Impact factor: 4.200

5.  Transporters in Regulatory Science: Notable Contributions from Dr. Giacomini in the Past Two Decades.

Authors:  Lei Zhang; Qi Liu; Shiew-Mei Huang; Robert Lionberger
Journal:  Drug Metab Dispos       Date:  2022-06-29       Impact factor: 3.579

6.  Important roles of transporters in the pharmacokinetics of anti-viral nucleoside/nucleotide analogs.

Authors:  Mengbi Yang; Xin Xu
Journal:  Expert Opin Drug Metab Toxicol       Date:  2022-09-09       Impact factor: 4.936

Review 7.  Pharmacogenomics of drug transporters for antiretroviral long-acting pre-exposure prophylaxis for HIV.

Authors:  Nomusa M Zondo; Parveen Sobia; Aida Sivro; Sinaye Ngcapu; Veron Ramsuran; Derseree Archary
Journal:  Front Genet       Date:  2022-09-29       Impact factor: 4.772

8.  Gene-by-Environment Interaction of Bcrp-/- and Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Steatohepatitis Alters SN-38 Disposition.

Authors:  Erica L Toth; Hui Li; Anika L Dzierlenga; John D Clarke; Anna Vildhede; Michael Goedken; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2018-08-30       Impact factor: 3.922

9.  High Throughput Screening of a Prescription Drug Library for Inhibitors of Organic Cation Transporter 3, OCT3.

Authors:  Eugene C Chen; Pär Matsson; Mina Azimi; Xujia Zhou; Niklas Handin; Sook Wah Yee; Per Artursson; Kathleen M Giacomini
Journal:  Pharm Res       Date:  2022-01-28       Impact factor: 4.580

10.  Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure.

Authors:  Ayako Tsuboya; Yutaro Kubota; Hiroo Ishida; Ryotaro Ohkuma; Tomoyuki Ishiguro; Yuya Hirasawa; Hirotsugu Ariizumi; Takuya Tsunoda; Yasutsuna Sasaki; Natsumi Matsumoto; Yusuke Kondo; Yukana Tomoda; Hiroyuki Kusuhara; Ken-Ichi Fujita
Journal:  Cancer Chemother Pharmacol       Date:  2021-06-11       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.